Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 2500 • 2016 ACR/ARHP Annual Meeting
Prevalence of Sustained Remission in Patients with Rheumatoid Arthritis in Sweden. Impact of Criteria Sets and Early Treatment, a Nationwide Register Study in Sweden
Jon T. Einarsson¹, Minna Willim¹, Sofia Ernestam^2,3, Tore Saxne¹, Pierre Geborek¹ and Meliha C. Kapetanovic¹, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Clinical Epidemiology unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ³Centre of Rheumatology, Stockholm County Council, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: The Swedish Society for Rheumatology guidelines recommend remission as treatment goal for patients with rheumatoid arthritis (RA). The Swedish quality registry (SRQ) is a…
Abstract Number: 2513 • 2016 ACR/ARHP Annual Meeting
Maintained Remission in Rheumatoid Arthritis over 7 Years in «Real Life Conditions» : A Monocentric Observational Study
Justine Vix¹, Elodie Loppin¹ and Elisabeth Solau-Gervais², ¹Rheumatology, University Hospital Poitiers, Poitiers, France, ²rheumatology, University Hospital Poitiers, Poitiers, France
Background/Purpose: Remission constitutes the best achievable state in patients with rheumatoid arthritis (RA). And if remission is a goal, it need to be maintained. The…
Abstract Number: 2524 • 2016 ACR/ARHP Annual Meeting
Achievement of Imaging Remission Among Patients with Rheumatoid Arthritis in Clinical Remission and Their Characteristics
Ji-Young Choi¹, Ran Song², Seung-Jae Hong¹, Hyung-In Yang², Sang-Hoon Lee² and Yeon-Ah Lee¹, ¹Rheumatology, Kyung Hee University Hospital, Seoul, South Korea, ²Rheumatology, Kyung Hee University Hospital at Gang dong, Seoul, South Korea
Background/Purpose: Therapeutic goal of rheumatoid arthritis (RA) is to achieve disease remission. However, several remission criteria have not always equated to the complete absence of…
Abstract Number: 2534 • 2016 ACR/ARHP Annual Meeting
Radiographic Remission in Patients with Seropositive RA at Ten Years after Diagnosis, Treated in a Real Life Setting
Tuulikki Sokka¹, Juha Asikainen¹, Tuomas Rannio^1,2 and Pekka Hannonen¹, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Radiographs of hands and feet represent an objective outcome measure of rheumatoid arthritis (RA). Joint damage is a result of cumulative disease activity over…
Abstract Number: 518 • 2016 ACR/ARHP Annual Meeting
Contribution of Patient Global Assessment on Loss and Gain of Disease Remission in Patients with Established Rheumatoid Arthritis in Clinical Practice
George A. Karpouzas¹, Elizabeth Hernandez², Chelsie Cost² and Sarah Ormseth², ¹Harbor UCLA Medical Center, Torrance, CA, ²Rheumatology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Patient global assessment (PGA) is part of the remission definitions in Rheumatoid arthritis (RA). We explored the proportion of patients who fail to achieve…
Abstract Number: 2587 • 2016 ACR/ARHP Annual Meeting
The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission
Arata Nakajima¹, Keiichiro Yamamoto² and Koichi Nakagawa³, ¹Orthopaedics, Toho University Sakura Medical Center, Sakura, Japan, ²Orthopedics, Toho University Sakura Medical Center, Sakura, Japan, ³Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
Abstract Number: 534 • 2016 ACR/ARHP Annual Meeting
Discordance Between Physician-Stated Remission and 28-Joint Disease Activity Score (DAS28)-Defined Remission in Rheumatoid Arthritis Patients
Nan Li¹, Stuart Blackburn², Emma Sullivan², Danuta Kielar¹ and Steve Peterson¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²Adelphi Real World, Manchester, United Kingdom
Background/Purpose: Data were drawn from the 2014 Adelphi RA Disease Specific Programme in 5 European countries (France, Germany, Italy, Spain, UK). Rheumatologists provided details about…
Abstract Number: 2621 • 2016 ACR/ARHP Annual Meeting
Incremental Benefit of Radiographic Inhibition on Long-Term Outcomes in Patients with Rheumatoid Arthritis
Edward C. Keystone¹, Keith A. Betts², Casey A. Schlacher³, Yan Song², Arijit Ganguli³ and Jenny Griffith³, ¹University of Toronto, Toronto, ON, Canada, ²Analysis Group, Inc., Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: For the treatment of rheumatoid arthritis (RA) a therapeutic window of opportunity exists– patients treated early have favorable outcomes compared with patients treated after…
Abstract Number: 545 • 2016 ACR/ARHP Annual Meeting
Utility of Power Doppler Ultrasound-Detected Synovitis for the Prediction of Short Term Flare in Rheumatoid Arthritis Patients in Clinical Remission
Facundo Vergara¹, Santiago Ruta¹, Johana Zacariaz¹, Josefina Marin¹, Javier Rosa¹, Ricardo Garcia-Monaco² and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Ultrasound has been shown to detect subclinical synovitis in patients who are in clinical remission, in rheumatoid arthritis (RA). The value of power Doppler…
Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Raimon Sanmarti¹, Jose Inciarte-Mundo¹, Paula Estrada², Maria García Manrique³, Javier Narváez⁴, Antonio Gomez-Centeno³, Jesús Rodríguez-Moreno⁴, Mariona Pascal⁵ and Jordi Yagüe⁵, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Moisès Broggi-Hospital General de L'Hospitalet - Consorci Sanitari Integral, Sant Joan Despí, Spain, ³Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ⁵Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…
Abstract Number: 555 • 2016 ACR/ARHP Annual Meeting
HAQ Score Is an Independent Predictor of Sustained Remission in Patients with Rheumatoid Arthritis
Ji-Eun Kim¹, Kyung-Eun Lee², Ji-Hyoun Kang², Yi-Rang Yim¹, Jeong-Won Lee¹, Lihui Wen¹, Dong-Jin Park², Tae-Jong Kim³, Yong-Wook Park² and Shin-Seok Lee³, ¹Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, The Republic of
Background/Purpose: We compared remission rates, according to different definitions of remission in rheumatoid arthritis (RA) and investigated the potential predictors of sustained remission at the…
Abstract Number: 3085 • 2016 ACR/ARHP Annual Meeting
Do Depression and Anxiety Reduce the Chance of Remission in Rheumatoid Arthritis and Psoriatic Arthritis?
Brigitte Michelsen^1,2, Karen M Fagerli¹, Elisabeth Lie¹, Hilde Berner Hammer³, Glenn Haugeberg^4,5, Eirik K Kristianslund¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁵Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Depression and anxiety are reported to predict poorer treatment outcomes in rheumatoid arthritis (RA).1 Whether this can be confirmed in larger, prospective studies as…
Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
KAZUYUKI YOSHIZAKI, Organic Fine Chemicals, The Institute of Scientific and Industrial Research, Osaka University, Suita, Japan
Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…
Abstract Number: 563 • 2015 ACR/ARHP Annual Meeting
Abatacept Plus Methotrexate Can Effectively and Safely Regain the Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early Rheumatoid Arthritis
Paul Emery¹, G Burmester², VP Bykerk³, B Combe⁴, Daniel E. Furst⁵, M Maldonado⁶ and T. W. J. Huizinga⁷, ¹University of Leeds, Leeds, United Kingdom, ²Charité – University Medicine Berlin, Berlin, Germany, ³Hospital for Special Surgery, New York, NY, ⁴Service d’Immuno-Rheumatologie, Montpellier, France, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Assessing Very Early Rheumatoid arthritis Treatment (AVERT) was a Phase IIIb, randomized, active-controlled study to evaluate the efficacy and safety of abatacept (ABA) treatment…
Abstract Number: 620 • 2015 ACR/ARHP Annual Meeting
Evaluation of Patients from the Non-Biologic Arms of Inflammatory Arthritis Clinical Trials Identifies Several Predictors of Remission, As Well As, Distinct Responder Subgroups
Brian Tom¹ and Deborah P.M. Symmons², ¹Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: The RA-MAP consortium is a UK flagship industry-academic partnership investigating clinical and biological predictors of disease outcome in patients with rheumatoid arthritis (RA). Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].